New: NCI-funded clinical trial search
Mednet Logo
CommunityRheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

How do you manage worsening cutaneous dermatomyositis when muscle disease appears controlled?

4
4 Answers

Mednet MemberInvited Expert
Rheumatology · The University of Texas Health Science Center at Houston (UTHealth)

The fact that the patient still has an active pruritic rash while tapering steroids suggests that the current regimen isn't fully controlling the disease, and it can affect quality of life. I would consider adjusting immunosuppression, either adding another agent or switching therapies. The specific...

Do you routinely recommend antibiotic prophylaxis for routine dental cleaning in patients taking mycophenolate mofetil?

1
2 Answers

Mednet MemberInvited Expert
Infectious Disease · Zucker School of Medicine at Hofstra/Northwell

The most recent AHA and ADA guidelines continue to recommend antibiotic prophylaxis prior to dental procedures for patients at high risk of developing endocarditis (Goff et al., PMID 31728507). Additional recommendations from the ADA include avoiding routine dental care for the first 6 months after ...

How would you treat SLE (inflammatory arthritis, +ANA/dsDNA/SSA) overlap with RA (CCP high titer) in a young female of childbearing age with low TPMT?

2 Answers

Mednet MemberInvited Expert
Rheumatology · Uniformed Services University of the Health Sciences (USUHS)

Whenever I have a patient with more than one systemic autoimmune disease, I often wonder which genotype/endotype is driving which manifestation. In this case... is it truly RA-driven inflammatory arthritis, or is it SLE arthritis? Depending on the cohort, around 25% of SLE patients are anti-CCP posi...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

Do you recommend allopurinol desensitization in gout patients who develop a rash on allopurinol therapy?

1
2 Answers

Mednet MemberInvited Expert
Rheumatology · National institues of Health

I don't recommend desensitization for allopurinol-allergic patients. There was a time when this made sense due to the lack of a viable alternative therapy. The process is cumbersome in a private practice setting and not as simple as providing the patient with a prescription for febuxostat.Febuxostat...

Should the use of avacopan be limited to those patients at increased risk of steroid toxicity given the anticipated high cost of this medication?

1
1 Answers

Mednet MemberInvited Expert
Rheumatology · Mayo Clinic College of Medicine

Once Avacopan is available for clinical use in the treatment of patients with AAV, providers will need to carefully weigh risks and benefits of the medication while considering other factors including cost.The ADVOCATE trial used a novel glucocorticoid toxicity index that captures common GC-related ...

In a young patient who was vaccinated against chickenpox as a child (no previous varicella infection), should the patient receive a shingles vaccine prior to starting Rinvoq?

2
5 Answers

Mednet MemberInvited Expert
Gastroenterology · Northwestern Medicine

Yes. The vaccines are different and current vaccine is to prevent zoster for patients who have been previously exposed to varicella or vaccinated for varicella.

What strategies have you found most effective in improving long-term medication adherence in patients with SLE?

2
2 Answers

Mednet MemberInvited Expert
Rheumatology · Penn Medicine

Patient education and buy-in are key for achieving long-term medication adherence. Medication adherence is the outcome of several factors, including but not limited to access to healthcare: appointments, laboratory visits, transportation, health literacy, medication fatigue, and response to therapy,...

In patients treated with infliximab, do rates of immunogenicity vary based on underlying disease (RA, IBD, sarcoidosis, etc) and/or baseline disease activity?

2
1 Answers

Mednet MemberInvited Expert
Rheumatology · Harvard Medical School

Yes, rates of infliximab immunogenicity appear to vary based on underlying disease, with evidence showing higher rates for RA than IBD and spondyloarthritis, and tend to increase with higher baseline disease activity. Most patients tend to develop anti-drug antibodies within the first year, but this...

Is there a period of time after which you would not resume ICI after a patient has had an irAE and required a prolonged steroid taper?

1 Answers

Mednet Member
Medical Oncology · Johns Hopkins University School of Medicine

Typically if a patient has required treatment with steroids for four to six months, it was because their irAE was significant (grade 2-4) and refractory to initial treatment. If the patient received combination immunotherapy, such as anti-CTLA-4 and anti-PD-1 agents, one could consider resuming the ...

How often do you draw screening ANAs for discoid lupus?

1
4 Answers

Mednet MemberInvited Expert
Rheumatology · Harvard Medical School

Because a positive ANA is associated with an increased risk of progression to SLE in patients with discoid lupus, I routinely check an ANA at the initial visit in virtually all patients. If negative, I repeat it only if new symptoms concerning systemic involvement arise (e.g., joint pain, cytopenias...